MICROALGAE BIOPOLYMERS: A REVIEW

Algae are ubiquitous organisms whose capabilities have drawn much attention as of late in the bioengineering field due to their potential to enable a wide range of bioproducts. Microalgae are ideal organisms for the application of the biorefinery concept since they can be grown in wastewater and, at the same time, produce many products of commercial interest. These microorganisms are also known for their resilience to extreme environmental conditions and suitable cell growth rates. Beyond the known potential for biofuel production, these microorganisms can still produce other compounds, being lipids, pigments, vitamins, proteins, and polysaccharides, whose applications go from pharmaceutical to agricultural industries. Recently, the research focus has been directed to the biopolymer-producing ability of both micro- and macroalgae, as they can be rather varied and useful to many applications. However, this is still an ongoing research field, and new data are frequently added in the literature, notably on biomass processing, which can be done with the intent of use into dyes, bioplastics, paints, and even as biochar in solid fuel cells. Microalgae-based biopolymers can be used in a wide range of products, nevertheless, the resulting process efficiency and yields depend on the extraction process utilized, as well as on the microalgae species used and the culture conditions. Furthermore, the polymer extraction can be done directly with common solvents at atmospheric pressure or with other fluids, such as supercritical CO2 or subcritical solvents, and assisted by specific treatments, e.g., ultrasound and microwave. The residual biomass can still be used to produce other less valuable products, such as feedstock, and energy via combustion. In this sense, the present work aims to provide a state-of-the-art review on microalgae biopolymers. Issues related to the efficiency of current treatment methods, industrial applications, and environmental performance are presented and discussed. Besides, the perspectives in this area of knowledge are also a contribution of the present work, the extent to which scientific research is still under development

2D seismic tomography of Somma-Vesuvius: Description of the experiment and preliminary results

A multidisciplinary project for the investigation of Mt. Vesuvius structure was started in 1993. The core of the project is represented by a high resolution seismic tomography study by using controlled and natural sources. The main research objective is to investigate the feeding system of the volcano and to retrieve details of the upper crustal structure in the area. A first 2D active seismic experiment was performed in May 1994, with the aim of studing the feasibility of using tomographic techniques for exploring the volcano interiors. Particularly, this experiment was designed to obtain information on the optimal sources-receivers configuration and on the depth extension of the volume sampled by shot-generated seismic waves. 66 three-component seismic stations and 16 single-component analogue instruments were installed by several Italian and French groups to record signals generated by three on-land, underground explosions. Sources and geophones were deployed along a 30-km NW-SE profile passing through the volcano crater. Receivers were placed at an average spacing of 250 m in the middle of the recording line and at 500 m outside. The arrival time data base was complemented by first P and S readings of microearthquakes which occurred in the recent past within the volcano. The first arrival data set was preliminarily used to determine the shallow structure of the volcano by applying Thurber's (1983) tomographic inversion technique. This analysis shows evidence for a high-velocity body which extends vertically from about 400 m below the crater down to at least 3000 m and for a shallow 300-500 m thick low-velocity cover which borders the edifice. Data from the distant shot show evidence for arrivals of deep reflected/converted phases and provide information on the deeper structure under the volcano. The results from the interpretation of 2D data are used for planning a 3D tomographic survey which will be carried out in 1996

Development and Validation of the Career Competencies Indicators (CCI)

This paper describes the development and validation of the Career Competencies Indicator (CCI); a 43-item measure to assess career competencies. Following an extensive literature review, a comprehensive item generation process involving consultation with subject matter experts, a pilot study and a factor analytic study on a large sample yielded a seven factor structure; goal setting and career planning, self-knowledge, job-performance, career-related skills, knowledge of (office) politics, career guidance and networking, and feedback seeking and self-presentation. Coefficient alpha reliabilities of the seven dimensions ranged from .93 to .81. Convergent validity was established by showing below chance similarity between CCI sub-scales, and discrminant validity between the CCI sub-scales and the big five personality scales. The results also suggested criterion-related validity of the CCI, since career competencies were found to jointly predict objective and subjective career success

The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers

Care for head and neck cancers is complex in particular for the rare ones. Knowledge is limited and histological heterogeneity adds complexity to the rarity. There is a wide consensus that to support clinical research on rare cancer, clinical registries should be developed within networks specializing in rare cancers. In the EU, a unique opportunity is provided by the European Reference Networks (ERN). The ERN EURACAN is dedicated to rare adults solid cancers, here we present the protocol of the EURACAN registry on rare head and neck cancers (ClinicalTrials.gov Identifier: NCT05483374). Study design Registry-based cohort study including only people with rare head and neck cancers. Objectives 1.To help describe the natural history of rare head and neck cancers; 2.To evaluate factors that influence prognosis; 3.To assess treatment effectiveness; 4.To measure indicators of quality of care. Methods Settings and participants It is an hospital based registry established in hospitals with expertise in head and neck cancers. Only adult patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middle ear will be included in the registry. This registry won t select a sample of patients. Each patient in the facility who meets the above mentioned inclusion criteria will be followed prospectively and longitudinally with follow-up at cancer progression and / or cancer relapse or patient death. It is a secondary use of data which will be collected from the clinical records. The data collected for the registry will not entail further examinations or admissions to the facility and/or additional appointments to those normally provided for the patient follow-up. Variables Data will be collected on patient characteristics (eg. patient demographics, lifestyle, medical history, health status); exposure data (eg. disease, procedures, treatments of interest) and outcomes (e.g. survival, progression, progression-free survival, etc.). In addition, data on potential confounders (e.g. comorbidity; functional status etc.) will be also collected. Statistical methods The data analyses will include descriptive statistics showing patterns of patients and cancers variables and indicators describing the quality of care. Multivariable Cox s proportional hazards model and Hazard ratios (HR) for all-cause or cause specific mortality will be used to determine independent predictors of overall survival, recurrence etc. Variables to include in the multivariable regression model will be selected based on the results of univariable analysis. The role of confounding or effect modifiers will be evaluated using stratified analysis or sensitivity analysis. To assess treatment effectiveness, multivariable models with propensity score adjustment and progression-free survival will be performed. Adequate statistical (eg. marginal structural model) methods will be used if time-varying treatments/ confounders and confounding by indication (selective prescribing) will be present. Results The registry initiated recruiting in May 2022. The estimated completion date is December 2030 upon agreement on the achievement of all the registry objectives. As of October 2022, the registry is recruiting. There will be a risk of limited representativeness due to the hospital-based nature of the registry and to the fact that hospital contributing to the registry are expert centres for these rare cancers. Clinical Follow-up could also be an issue but active search of the life status of the patients will be guaranteed

α-thalassaemia

Alpha-thalassaemia is inherited as an autosomal recessive disorder characterised by a microcytic hypochromic anaemia, and a clinical phenotype varying from almost asymptomatic to a lethal haemolytic anaemia

The use of digital pathology and image analysis in clinical trials

Digital pathology and image analysis potentially provide greater accuracy, reproducibility and standardisation of pathology‐based trial entry criteria and endpoints, alongside extracting new insights from both existing and novel features. Image analysis has great potential to identify, extract and quantify features in greater detail in comparison to pathologist assessment, which may produce improved prediction models or perform tasks beyond manual capability. In this article, we provide an overview of the utility of such technologies in clinical trials and provide a discussion of the potential applications, current challenges, limitations and remaining unanswered questions that require addressing prior to routine adoption in such studies. We reiterate the value of central review of pathology in clinical trials, and discuss inherent logistical, cost and performance advantages of using a digital approach. The current and emerging regulatory landscape is outlined. The role of digital platforms and remote learning to improve the training and performance of clinical trial pathologists is discussed. The impact of image analysis on quantitative tissue morphometrics in key areas such as standardisation of immunohistochemical stain interpretation, assessment of tumour cellularity prior to molecular analytical applications and the assessment of novel histological features is described. The standardisation of digital image production, establishment of criteria for digital pathology use in pre‐clinical and clinical studies, establishment of performance criteria for image analysis algorithms and liaison with regulatory bodies to facilitate incorporation of image analysis applications into clinical practice are key issues to be addressed to improve digital pathology incorporation into clinical trials

What to do and what not to do in the management of cancer pain: A physician survey and expert recommendations

Background: Despite the prevalence of pain among patients with cancer and the availability of pertinent guidelines, the clinical management of oncological pain is decisively insuffi-cient. To address this issue, we evaluated current trends in clinical practice and subsequently generated a list of ten corrective actions—five things to do and five things not to do—for the diagnosis, management, and monitoring of cancer pain. Methods: The survey included 18 questions about clinical practice surrounding background pain and breakthrough cancer pain (BTcP). Survey questions were developed by a scientific board of 10 physician experts and communicated via email to an expanded panel of physicians in Italy. Responses were tabulated descriptively for analysis. Results: Of 51 invited physicians, 32 (63%) provided complete survey responses. The responses revealed several incongruencies with current guideline recommendations: physicians did not always diagnose or monitor pain using diagnostically validated or disease-specific instruments; frequently based clinical decision-making on time availability or convenience; and pharmacological therapy was often inappropriate (eg, prescribing NSAIDs or corticosteroids for BTcP). The list of corrective actions generated by the scientific board favored a guideline-oriented approach that systematically characterizes oncological pain and implements treatment based on pain character-istics (eg, fast-acting transmucosal opioids for BTcP) and evidence-based recommendations. Conclusion: Oncologists require better education and training about the diagnosis, treat-ment, and monitoring of oncological pain. Physicians should be aware of current guideline recommendations as well as available pharmacological tools for BTcP